1. Home
  2. |Insights
  3. |Terrell McSweeny Confirmed as Fifth FTC Commissioner

Terrell McSweeny Confirmed as Fifth FTC Commissioner

Client Alert | 1 min read | 04.10.14

In 95-1 vote yesterday, the U.S. Senate confirmed President Obama's nomination of Terrell McSweeny as the fifth commissioner at the Federal Trade Commission (FTC). McSweeny's confirmation—almost ten months after she was first nominated—fills the vacancy that was created when former Chairman Jon Leibowitz stepped down in February of 2013.

McSweeny's confirmation is significant in that it restores the Democrat's 3-2 majority on the Commission. McSweeny joins Chairwoman Edith Ramirez and Julie Brill in the majority; Maureen Ohlhausen and Joshua Wright are the two Republican Commissioners. Prior to McSweeny's confirmation, in the case of 2-2 tie, the FTC would decline to intervene.

Prior to her nomination, McSweeny worked with Vice President Biden between 2005 and 2012 in various roles, including as his deputy chief of staff, as counsel on the Senate Judiciary Committee, and as his domestic policy advisor. More recently, McSweeny served as senior counsel of competition policy in the Antitrust Division at the Department of Justice.

McSweeny brings expertise in a variety of industries, including health insurance, health care, consumer products and a wide range of policy issues. During her September 2013 confirmation hearings, McSweeny vowed to protect the middle class through competition and consumer protection enforcement, including privacy regulations. Among other things, McSweeny discussed the need to protect children's privacy, the rapidly evolving mobile technology landscape, and the necessity for public education with respect to online data collection.

McSweeny is a graduate of Harvard University and Georgetown University Law School.

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...